Systemic bis-phosphinic acid derivative restores chloride transport in Cystic Fibrosis mice

Archive ouverte

da Cunha, Mélanie Faria | Pranke, Iwona | Sassi, Ali | Schreiweis, Christiane | Moriceau, Stéphanie | Vidovic, Dragana | Hatton, Aurélie | Carlon, Mariane Sylvia | Creste, Geordie | Berhal, Farouk | Prestat, Guillaume | Freund, Romain | Odolczyk, Norbert | Jais, Jean-Philippe | Gravier-Pelletier, Christine | Zielenkiewicz, Piotr | Jullien, Vincent | Hinzpeter, Alexandre | Oury, Franck | Edelman, Aleksander | Sermet-Gaudelus, Isabelle

Edité par CCSD ; Nature Publishing Group -

International audience. Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene (CFTR) are responsible for Cystic Fibrosis (CF). The most common CF-causing mutation is the deletion of the 508th aminoacid of CFTR (F508del), leading to dysregulation of the epithelial fluid transport in the airway's epithelium and the production of a thickened mucus favoring chronic bacterial colonization, sustained inflammation and ultimately respiratory failure. c407 is a bis-phosphinic acid derivative which corrects CFTR dysfunction in epithelial cells carrying the F508del mutation. This study aimed to investigate c407 in vivo activity in the F508del Cftr tm1Eur murine model of CF. Using nasal potential difference measurement, we showed that in vivo administration of c407 by topical, short-term intraperitoneal and long-term subcutaneous route significantly increased the CFTR dependent chloride (Cl −) conductance in F508del Cftr tm1Eur mice. This functional improvement was correlated with a relocalization of F508del-cftr to the apical membrane in nasal epithelial cells. Importantly, c407 long-term administration was well tolerated and in vitro ADME toxicologic studies did not evidence any obvious issue. Our data provide the first in vivo preclinical evidence of c407 efficacy and absence of toxicity after systemic administration for the treatment of Cystic Fibrosis.

Suggestions

Du même auteur

New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation

Archive ouverte | Bitam, Sara | CCSD

International audience. C407 is a compound that corrects the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein carrying the p.Phe508del (F508del) mutation. We investigated the corrector effect of c4...

Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain

Archive ouverte | Odolczyk, Norbert | CCSD

International audience. The deletion of Phe508 (ΔF508) in the first nucleotide binding domain (NBD1) of CFTR is the most common mutation associated with cystic fibrosis. The ΔF508-CFTR mutant is recognized as improp...

Modulators of CFTR. Updates on clinical development and future directions

Archive ouverte | Bardin, Emmanuelle | CCSD

International audience

Chargement des enrichissements...